Contact Lens Wear
Mild
Database
Benzalkonium chloride preservative absorbed by lenses
Remove lenses; reinsert after 10 min
Source: Kimi deep-research + Cla
Drug reference
olopatadine hydrochloride
Second-generation H1 antihistamine / mast-cell stabiliser · Antiallergy
START
Ophthalmic 0.1% 1 drop BID; nasal 0.6% 2 sprays/nostril BID
TYPICAL MAX
Ophthalmic up to TID; nasal 2 sprays/nostril BID
STOP IF
Severe hypersensitivity
WATCH
Local tolerance; allergen avoidance
CDSCO approvedATC S01GX09
KDIGO 2024 + manufacturer label
- ONSET
- 6min · local onset
- PEAK
- 2h · peak effect
- t½
- 3h · t½ (systemic)
- DURATION
- 12h · BID
EXCRETION
Renal — minimal systemic
route + CYP
INTERACTIONS
—
none in our sources
PREGNANCY
Limited data; topical use acceptable.
FDA category + note
Mechanism
Selective H1-receptor antagonist with mast-cell-stabilising activity (inhibits histamine, leukotriene and cytokine release from mast cells); used topically for ocular allergy and intranasally for allergic rhinitis.
Indications
Allergic conjunctivitis (ophthalmic)Allergic rhinitis (intranasal)
Dosing
- Adult
- Ophthalmic 0.1%: 1 drop in affected eye(s) twice daily; 0.2% or 0.7%: 1 drop once daily. Nasal 0.6%: 2 sprays per nostril twice daily.
- Pediatric
- Ophthalmic ≥3 y: as adult. Nasal ≥6 y: as adult.
- Renal adjustment
- No adjustment (topical).
- Hepatic adjustment
- No adjustment.
- Geriatric
- Standard topical use.
- Max dose
- Ophthalmic up to TID; nasal 2 sprays per nostril BID
Pharmacokinetics
Onset
Symptom relief within minutes
Peak effect
~2 h post-instillation
Duration
Ophthalmic ~8–24 h; nasal ~12 h
Half-life
~3 h (systemic, if absorbed)
Bioavailability
Low systemic (~1–2% ophthalmic)
Protein binding
~55%
Metabolism
Minimal hepatic
Excretion
Renal
Contraindications
- Hypersensitivity to olopatadine
Side effects
Common
Local burning / stingingHeadacheDry mouthBitter taste (nasal)Mild eye irritation
Serious
- Severe hypersensitivity (rare)
Pregnancy & lactation
Pregnancy
Limited data; topical use acceptable.
Lactation
Compatible (negligible systemic absorption).
Drug interactions
Other Antihistamines
Mild
Database
Duplicate therapy
Avoid duplicate ophthalmic agents
Source: Kimi deep-research + Cla
Other Topical Eye Drops
Mild
Database
Possible dilution
Separate instillation by ≥5 min
Source: Kimi deep-research + Cla
Systemic Antihistamines
Mild
Database
Additive (rare given negligible systemic)
Routine use
Source: Kimi deep-research + Cla
Topical Corticosteroids
Mild
Database
Combination treatment (intended for severe cases)
Per protocol
Source: Kimi deep-research + Cla
Related guidelines
Ask House about olopatadine hydrochloride
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Goodman & Gilman 14e·Verified: 2026-05-20 · House clinical team·Cockpit curated: 2026-05-20